NVC-422 (NovaBay) shows potential against adenoviral Conjuctivitis

A new study has demonstrated the virucidal activity of NVC-422 (aganocide) against adenovirus type 5 that causes Conjunctivitis. In vitro assays show that NVC-422 has a good therapeutic index and the virucidal activity of NVC-422 is rapid with complete inactivation of Ad5 within 15 min. The virucidal activity of NVC-422 is due to its reacting with key viral proteins. If untreated, adenoviral conjunctivitis can further develop into keratitis, corneal ulceration, scarring and possible blindness. See: "Virucidal mechanism of action of NVC-422, a novel antimicrobial drug for the treatment of adenoviral conjunctivitis" by Jungjoo Yoon et al. Antiviral Research, Volume 92, Issue 3, December 2011, Pages 470-478